Gain Therapeutics (GANX) Enterprise Value (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Enterprise Value of -$16.5 million for Q1 2026, down 82.35% year-over-year from -$93.7 million in Q1 2025, and up 20.63% quarter-over-quarter from -$20.8 million in Q4 2025.
Gain Therapeutics (GANX) Enterprise Value (2020 - 2026) Analysis & Trends
Gain Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$16.5 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 82.35% year-over-year to -$16.5 million; the TTM figure through Mar 2026 stood at -$16.5 million (down 82.35% YoY), while the FY2025 annual figure was -$20.8 million, down 100.63% from the prior year.
- Enterprise Value for Q1 2026 stood at -$16.5 million, up from -$20.8 million in the prior quarter.
- The five-year high for Enterprise Value was -$6.7 million in Q2 2025, with the low at -$34.3 million in Q1 2022.
- The 5-year median for Enterprise Value is -$16.5 million (2026), against an average of -$16.4 million.
- Peak annual rise in Enterprise Value reached 60.47% in 2025, while the deepest fall reached 100.63% in 2025.
- Gain Therapeutics' Enterprise Value stood at -$20.1 million in 2022, then climbed by 16.6% to -$16.8 million in 2023, then jumped by 38.16% to -$10.4 million in 2024, then sank by 100.63% to -$20.8 million in 2025, then grew by 20.63% to -$16.5 million in 2026.
- Business Quant data shows GANX's Enterprise Value at -$16.5 million in Q1 2026, -$20.8 million in Q4 2025, and -$8.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Gain Therapeutics | 85.12 Mn | 85.12 Mn | - | -13.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.10 Mn |
| Mar 31, 2026 | -16.54 Mn |
| Dec 31, 2025 | -20.84 Mn |
| Sep 30, 2025 | -8.80 Mn |
| Jun 30, 2025 | -6.69 Mn |
| Mar 31, 2025 | -9.07 Mn |
| Dec 31, 2024 | -10.39 Mn |
| Sep 30, 2024 | -12.00 Mn |
| Jun 30, 2024 | -16.94 Mn |
| Mar 31, 2024 | -12.66 Mn |
| Dec 31, 2023 | -16.79 Mn |
| Sep 30, 2023 | -12.23 Mn |
| Jun 30, 2023 | -16.19 Mn |
| Mar 31, 2023 | -17.82 Mn |
| Dec 31, 2022 | -20.14 Mn |
| Sep 30, 2022 | -22.73 Mn |
| Jun 30, 2022 | -24.25 Mn |
| Mar 31, 2022 | -34.34 Mn |
| Dec 31, 2021 | -36.88 Mn |
| Sep 30, 2021 | -40.98 Mn |